Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab-induced Crohn's disease.
Varma P, Falconer J, Aga A, Prince HM, Pianko S. Varma P, et al. Among authors: pianko s. Scand J Gastroenterol. 2017 May;52(5):606-608. doi: 10.1080/00365521.2017.1280530. Epub 2017 Jan 27. Scand J Gastroenterol. 2017. PMID: 28129697
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).
Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, Pol S, Stuart K, Tse E, McPhee F, Bhore R, Jimenez-Exposito MJ, Thompson AJ. Leroy V, et al. Among authors: pianko s. Hepatology. 2016 May;63(5):1430-41. doi: 10.1002/hep.28473. Epub 2016 Mar 4. Hepatology. 2016. PMID: 26822022 Free PMC article. Clinical Trial.
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Lubel J, Strasser S, Stuart KA, Dore G, Thompson A, Pianko S, Bollipo S, Mitchell JL, Fragomeli V, Jones T, Chivers S, Gow P, Iser D, Levy M, Tse E, Gazzola A, Cheng W, Nazareth S, Galhenage S, Wade A, Weltman M, Wigg A, MacQuillan G, Sasadeusz J, George J, Zekry A, Roberts SK; Australian Liver Association Clinical Research Network (ALA CRN). Lubel J, et al. Among authors: pianko s. Antivir Ther. 2017;22(8):699-710. doi: 10.3851/IMP3168. Antivir Ther. 2017. PMID: 28422043
Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.
Pianko S, Zeuzem S, Chuang WL, Foster GR, Sarin SK, Flisiak R, Lee CM, Andreone P, Piratvisuth T, Shah S, Sood A, George J, Gould M, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Li Y, Pang M, Yin Y, Feutren G, Jacobson IM; B2202 Study Team. Pianko S, et al. J Viral Hepat. 2012 Sep;19(9):623-34. doi: 10.1111/j.1365-2893.2012.01586.x. Epub 2012 Mar 21. J Viral Hepat. 2012. PMID: 22863266 Clinical Trial.
Induction interferon and ribavirin for re-treatment of chronic hepatitis C patients unresponsive to interferon alone.
Sievert W, Batey R, Mollison L, Pianko S, McDonald J, Marinos G, Reed W, Warner S, Bowden S, De Solom R, Bhathal P; AusHep Investigators. Sievert W, et al. Among authors: pianko s. Aliment Pharmacol Ther. 2003 May 1;17(9):1197-204. doi: 10.1046/j.1365-2036.2003.01544.x. Aliment Pharmacol Ther. 2003. PMID: 12752357 Free article. Clinical Trial.
57 results